BioMS Medical announces 17 additional patents for MS drug
The additional countries granting patents included Austria, Belgium, the Czech Republic, Denmark, Finland, France, Greece, Germany, Ireland, Luxembourg, Monaco, Netherlands, Spain, Sweden, Switzerland, Ukraine and the United Kingdom. In total, 50 patents have been granted to the University of Alberta for MBP8298 in 29 countries worldwide, including three patents issued in the United States.
"We continue to build a very powerful intellectual property portfolio for our lead product, MBP8298," said Kevin Giese, President of BioMS Medical.
"With patent protection in the United States, Canada and many of the key European countries where MS is highly present, the future commercial value of our MS drug is well protected."
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.